Matilde Lleonart Pajarin I am group leader of "Biomedical Research in Cancer Stem Cells" at VHIR. I arrived at VHIR 21 years ago after having worked in different prestigious international research centers: World Health Organization (WHO) at the International Agency for Research on Cancer (IARC) (Lyon, France), the Wolfson Institute for Biomedical Research (WIBR) in London and the Queen´s Mary University of London. Institutions of which they are part Head of group Head and Neck Cancer: Biomedical Research Cancer Stem cells Vall Hebron Institut de Recerca LinkedIn Twitter Orcid Matilde Lleonart Pajarin LinkedIn Twitter Orcid Institutions of which they are part Head of group Head and Neck Cancer: Biomedical Research Cancer Stem cells Vall Hebron Institut de Recerca I am group leader of "Biomedical Research in Cancer Stem Cells" at VHIR. I arrived at VHIR 21 years ago after having worked in different prestigious international research centers: World Health Organization (WHO) at the International Agency for Research on Cancer (IARC) (Lyon, France), the Wolfson Institute for Biomedical Research (WIBR) in London and the Queen´s Mary University of London.
My Research Group was recognized as an Emerging Research Group in 2009 by the Generalitat de Catalunya and later in 2014 as a Consolidated Research Group. Throughout my career I have been involved in cancer research from a more molecular point of view correlating key mutations in oncogenes and tumor suppressor genes with anatomical, pathological and clinical features of patients' tumors and also through cell culture studies to determine important key cell signaling pathways in tumorigenesis. Currently, the main lines of research of my Research Group focus on the identification and characterization of biological mechanisms in resistant cancer cells, including cancer stem cells, to unravel the pathways responsible for their resistance in breast, lung and head and neck cancer models. In addition, we are particularly focused on identifying molecular targets in resistant cancer cells and cancer stem cells affecting particularly aggressive tumors. The aim is to attack them pharmacologically in order to propose new cancer therapies: new drugs and/or drug combinations to combat resistant tumors in mouse models.
Projects Desarrollo de dianas terapéuticas basadas en micro-RNAs sobreexpresados en cáncer IP: Matilde Lleonart Pajarin Collaborators: - Funding agency: Fundación Caja Navarra Funding: 9463.18 Reference: CAN2009-16708 Duration: 01/01/2010 - 31/12/2010 Identificación de nuevas dianas terapéuticas basadas en micro-RNAs sobreexpresados en cáncer IP: Matilde Lleonart Pajarin Collaborators: Marc Pellicer Sarasa, Carmela Iglesias i Felip Funding agency: Instituto de Salud Carlos III Funding: 147015 Reference: PI09/02193 Duration: 01/01/2010 - 30/04/2013 Oncología y Patología Molecular IP: Matilde Lleonart Pajarin Collaborators: - Funding agency: Agència Gestió Ajuts Universitaris i de Recerca Funding: 39520 Reference: 2009 SGR 604 Duration: 01/01/2010 - 30/04/2014 Cirp function as a chaperone molecule interacting with RNA and microRNA and microRNAs IP: Santiago Ramon y Cajal Agüeras Collaborators: Matilde Lleonart Pajarin Funding agency: Agència Gestió Ajuts Universitaris i de Recerca Funding: 7600 Reference: 2007 BE-1 00296 Duration: 20/08/2007 - 20/12/2007 Pagination First page « Previous page ‹ … Page 5 Page 6 Current page 7 Page 8 Page 9 Next page › Last page »
